Hybio Pharmaceutical Co., Ltd. (SHE:300199)

Market Cap	16.51B
Revenue (ttm)	749.91M
Net Income (ttm)	-89.68M
Shares Out	883.24M
EPS (ttm)	-0.10
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	60,396,241
Average Volume	106,683,002
Open	19.60
Previous Close	18.69
Day's Range	18.52 - 19.60
52-Week Range	8.83 - 20.00
Beta	1.11
RSI	56.78
Earnings Date	Aug 22, 2025

About Hybio Pharmaceutical

Hybio Pharmaceutical Co., Ltd. engages in the development, manufacture, and commercialization of therapeutic peptides API and peptide-based drugs in China and internationally. It offers liraglutide, semaglutide, and exenatide for diabetes; terlipressin, desmopressin, and linaclotide for digestive tract and metabolic system; ganirelix, cetrorelix, and atosiban for obstetrics and gynecology; customized peptides; working standards for the peptide APIs and related impurities; peptide CRO; and CDMO services, which include peptide API synthesis and p...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1998
• Employees: 1,035
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300199

Financial Performance

In 2024, Hybio Pharmaceutical's revenue was 590.20 million, an increase of 36.82% compared to the previous year's 431.38 million. Losses were -173.65 million, -66.21% less than in 2023.